Premium
Influences of argatroban on five fibrinogen assays
Author(s) -
Zhang L.,
Yang J.,
Zheng X.,
Fan Q.,
Zhang Z.
Publication year - 2017
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.12719
Subject(s) - argatroban , fibrinogen , chemistry , thrombin , partial thromboplastin time , thrombin time , reagent , coagulation , medicine , pharmacology , platelet , biochemistry , organic chemistry
Argatroban, as a direct thrombin inhibitor, prolongs the clotting time. However, detection of clotting time is the base of routine fibrinogen assays, including Clauss method and derived method. The influences of argatroban on fibrinogen assays are still unclear. Methods Normal pooled plasma ( NPP ) from 20 healthy subjects was spiked with increasing argatroban concentrations (0‐3.2 μg/mL). Then the NPP samples were analyzed by five fibrinogen assays: Hemos IL Fibrinogen‐C XL reagent (Clauss method) on ACL ‐ TOP ; STA ‐Fibrinogen reagent (Clauss method) on STA ‐R Evolution; Siemens Thrombin reagent (Clauss method) on CS ‐5100; Synth AS il RecombiPlasTin 2G reagent ( PT ‐derived method) on ACL ‐ TOP ; and N Antiserum to Human Fibrinogen reagent ( NAHF , Immunoassay) on BN 2 nephelometer analyzer. Results Argatroban had no influences on NAHF ( P =.13). Compared with the NAHF , significant reduction was observed on Fibrinogen‐C XL ( P <.01), while no influences were shown on the others ( STA ‐Fibrinogen: P =.41, Siemens Thrombin: P =.20, RecombiPlasTin 2G: P =.21) when activated partial thromboplastin time (APTT) ratio was no more than 3.0. As APTT ratio was increasing to 4.5, results from Clauss and PT ‐derived methods were significantly lowered ( STA ‐Fibrinogen: P =.02, Siemens Thrombin: P <.01, Fibrinogen‐C XL : P <.01, RecombiPlasTin 2G: P <.01). Conclusion The influences of argatroban on fibrinogen assays differ greatly, clinicians should be aware of the influences of argatroban on the fibrinogen assays used on site to avoid misdiagnoses.